Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Correction: An earlier version of this article incorrectly referred to Mike Leach as the football coach at Texas A&M. In fact, Leach is the coach at Texas Tech, Mark Lanier’s alma mater.

Mark Lanier told The Am Law Litigation Daily on Friday that he’s not expecting any miracles on Monday, when he begins the first trial to test claims that Pfizer’s anti-epilepsy drug Neurontin increases patients’ risk of suicide. He’ll be lucky, he said, to eke out a win. “I’ve got a near impossible case,” Lanier told us. “If I lose, it’s almost like a focus group educational experiment. If I win, it portends bad things for Pfizer.” [Hat tip to Bloomberg, which offers this insightful trial preview.]

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.